Pfizer is trading like it caught a cold, despite showing strong financial health post-COVID. In Q4 2024, Pfizer raked in ...

Pfizer's stock is poised for growth due to its strong pipeline, smart cost management, and recovery from COVID-19 revenue ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Pfizer's attractive dividend yield and low P/E ratio make it appealing. Learn why PFE stock's valuation risks may be higher ...

Shares of Pfizer Inc. (NYSE:PFE – Get Free Report) have received a consensus rating of “Moderate Buy” from the seventeen ...

This week, the FDA approved J&J’s JNJ Tremfya for its second inflammatory bowel disease (“IBD”) condition, Crohn’s disease ...

AstraZeneca signed a deal with Alteogen worth up to $1.35 billion for subcutaneous cancer drugs. Taiho Pharmacetical bought ...

Here are three reasons why Pfizer could prove to be a steal of a deal this year. Buying quality stocks at decent valuations ...

Pfizer Inc. stands out as an undervalued biotech stock with strong dividend potential and ambitious oncology expansion. The company boasts a forward P/E of 8.82, making it significantly cheaper than ...

Pfizer has announced plans to sell its remaining stake in Haleon plc, divesting approximately 662 million shares.

We recently published a list of the 7 Most Undervalued Biotech Stocks To Invest In. In this article, we are going to take a ...

Drugmaker Pfizer has sold its entire stake in Haleon for about 2.5 billion pounds ($3.24 billion) to institutional investors ...